A lifetime breast cancer risk of 20% or greater is the widely used threshold for “high risk.” The American Cancer Society uses this cutoff to recommend enhanced screening, and most clinical guidelines follow the same benchmark. For context, the average woman’s lifetime risk is about 13%, so high risk means roughly 1.5 to several times that baseline. Some guidelines further distinguish an “intermediate risk” category for women with a lifetime risk between 15% and 20%.
But a single number doesn’t tell the whole story. Your lifetime risk is shaped by genetics, family history, personal medical history, breast density, and prior radiation exposure. Understanding which factors apply to you determines both your risk category and what you can do about it.
Genetic Mutations With the Highest Impact
Inherited gene mutations are the single largest driver of high-risk classification. BRCA1 carriers face a cumulative breast cancer risk of 40% to 87% by age 70. For BRCA2 carriers, estimates range from 27% to 84%. These numbers dwarf the general population risk and place carriers firmly in the highest-risk category from a relatively young age.
Beyond BRCA1 and BRCA2, several other gene mutations confer moderate to high risk. PALB2 carriers have an estimated 40% chance of developing breast cancer by age 80, which is comparable to BRCA2. CHEK2 mutations carry roughly a 28% lifetime risk, and ATM mutations about 22%. All three cross or approach the 20% threshold that triggers high-risk management, though the exact classification depends on which risk model your provider uses and whether other factors compound the genetic risk.
Family History That Raises Your Risk
Having a mother, sister, or daughter diagnosed with breast cancer roughly doubles your risk. That risk climbs further when multiple close relatives have been affected or when a relative was diagnosed before age 50. Specific family history patterns that typically warrant referral to a genetics clinic include:
- One first-degree female relative diagnosed before age 40
- One first-degree male relative diagnosed at any age
- One first-degree relative with cancer in both breasts, with the first diagnosed before age 50
- Two first-degree relatives, or one first-degree and one second-degree relative, diagnosed at any age
- A combination of breast cancer and ovarian cancer among first- or second-degree relatives
- Three or more first- or second-degree relatives diagnosed at any age
First-degree relatives are parents, siblings, and children. Second-degree relatives include aunts, uncles, grandparents, nieces, and nephews. Paternal family history counts just as much as maternal, even though it’s sometimes overlooked.
Breast Conditions That Increase Risk
Certain findings on a breast biopsy signal higher future risk even when they aren’t cancer themselves. Atypical ductal hyperplasia (ADH), a condition where cells in the milk ducts grow abnormally, carries a 10-year breast cancer risk of about 14%. That’s roughly 2.5 to 5 times the risk of women without the finding. Lobular carcinoma in situ (LCIS), abnormal cell growth in the milk-producing glands, has a similar profile: about a 12% risk over 10 years, or roughly four times the baseline risk.
Neither ADH nor LCIS is cancer, but both are markers that the breast tissue is more prone to developing cancer over time. Women with these diagnoses are often monitored more closely and may be candidates for risk-reducing medication.
Chest Radiation at a Young Age
Women who received radiation therapy to the chest before age 30, most commonly for Hodgkin lymphoma, face up to eight times the general population’s breast cancer risk. In one study, 34% of patients treated at age 30 or younger eventually developed breast cancer, with a median gap of 21 years between radiation and diagnosis. Risk begins to climb five to nine years after treatment, peaks between 15 and 19 years out, and remains elevated for 30 to 40 years.
Current guidelines recommend that these women begin annual breast cancer screening at age 25 or eight years after radiation (whichever comes later) and continue at least until age 60.
Breast Density as a Risk Factor
Extremely dense breast tissue (classified as BI-RADS category D on a mammogram) roughly doubles breast cancer risk compared to women with average density. A large meta-analysis found a 2.11-fold increase, and even after adjusting for age and body weight, the risk remained about 1.8 times higher.
Dense tissue also makes cancers harder to detect on standard mammograms because both dense tissue and tumors appear white on the image. This is why women with dense breasts and other risk factors are often recommended for supplemental screening with MRI or contrast-enhanced mammography. Many U.S. states now require that mammography reports inform you of your breast density category.
How Your Risk Is Calculated
Doctors use mathematical models to estimate your lifetime breast cancer risk as a percentage. The two most common are the Gail model and the Tyrer-Cuzick model, and they can give noticeably different results for the same woman.
The Gail model is simpler. It factors in age, reproductive history, prior biopsies, and first-degree family history only. It does not account for the age at which relatives were diagnosed, paternal family history, male breast cancer, or ovarian cancer in the family. The Tyrer-Cuzick model captures a more detailed family tree and tends to produce higher, more accurate risk estimates for women with significant family history. If your concern is driven by family history, the Tyrer-Cuzick model is generally considered more appropriate.
Risk assessment is recommended by age 25, particularly for Black women and women of Ashkenazi Jewish descent, who have higher rates of BRCA mutations. Your result determines whether you need screening earlier than the standard age of 40 and whether supplemental imaging is warranted.
Screening for High-Risk Women
If your lifetime risk is 20% or higher, guidelines recommend annual breast MRI in addition to annual mammography. For women with genetic mutations or a history of chest radiation, this enhanced screening typically starts between ages 25 and 30, depending on the specific risk factor. Women at high risk who cannot undergo MRI (due to claustrophobia, implanted devices, or other reasons) may be offered contrast-enhanced mammography as an alternative.
The combination of MRI and mammography catches significantly more cancers than mammography alone, particularly in dense breast tissue. The two tests complement each other because each detects cancers the other can miss.
Risk-Reducing Medications
For women identified as high risk, medications taken over five years can meaningfully reduce the chance of developing breast cancer. Two drugs are FDA-approved specifically for this purpose. Tamoxifen prevents about 7 cases of invasive breast cancer per 1,000 women over five years. Raloxifene, available only for postmenopausal women, prevents about 9 cases per 1,000. A third class of drugs, aromatase inhibitors, shows the strongest effect in trials, preventing about 16 cases per 1,000 women over five years, though they are not yet FDA-approved specifically for risk reduction.
All three work primarily against hormone receptor-positive breast cancers, which account for the majority of cases. The decision to take these medications involves weighing the reduction in breast cancer risk against side effects, which can include hot flashes, joint pain, and in rare cases, blood clots or uterine issues. Not every high-risk woman chooses medication, but it’s an option worth discussing if your calculated risk crosses the threshold.